Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tiziana

- PMLiVE

Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn

A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts

- PMLiVE

FDA rejects Provention Bio’s type 1 diabetes prevention drug

FDA said a study of healthy volunteers failed to demonstrate that the planned commercial product is comparable to an older version used in previous clinical trials

- PMLiVE

FDA panel backs Provention Bio’s type 1 prevention drug teplizumab

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) narrowly voted in favour of supporting approval of the drug

- PMLiVE

Vertex gains FDA fast track designation for diabetes stem cell therapy

Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients

- PMLiVE

Provention Bio wins PRIME designation for type 1 diabetes prevention drug

Meanwhile J&J partnered Crohn's drug flops in phase 2

- PMLiVE

Vertex eyes type 1 diabetes cure with biotech acquisition

Will acquire Semma Therapeutics for $950m

- PMLiVE

Tiziana joins type 1 diabetes prevention field

Cites potential advantages

- PMLiVE

Type 1 diabetes prevention promise sends Provention Bio soaring

Remarkable results prompt firm to consider regulatory pathway

- PMLiVE

Success for AZ, setback for Sanofi in type 1 diabetes

Forxiga approved as add-on to insulin

- PMLiVE

Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer

Company has reached milestone in stem cell therapy as it looks to broaden range beyond diabetes

Sanofi reception

Type 1 diabetes market to double to $13.6bn

New treatments will see this growth by 2023, according to GlobalData

- PMLiVE

The rising prevalence of diabetes in Europe

The condition is still an unstoppable epidemic

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links